MEB-1170
MEB-1170 is a clinical stage oral compound being developed to treat opioid use disorder
MEB-1170 is currently in Phase 1 Clinical Trials, it has successfully completed a Single Ascending Dose study in healthy human volunteers
Highlight of MEB-1170 Preclinical Data
Demonstrated Target Engagement
No Respiratory Depression
-
- Oral with long half-life
- As efficacious as morphine
- Confirmed in 3 in vivo pain models (Formalin Induced Pain, Post Incisional Pain, Tail Flick)
-
- Acute and chronic oral dosing
- Normal pO2, pCO2, pH
- Normal respiratory drive (Respiratory Rate, Minute Volume, Tidal Volume)
In other preclinical studies
-
- Does not produce tolerance
- Does not cause constipation
- Does not cause sedation
MEB-1170 Shows no abuse potential in preclinical models of abuse for CNS drugs
No Drug Seeking Behavior
No Self-Administration
Minimal Withdrawal
Drug Discrimination
MEB-1170 has the potential to prevent and to treat opioid misuse
Rats self-administering Oxycodone do not self-administer MEB-1170
Rats pre-treated with MEB-1170 do not self-administer Oxycodone
